Wall Street brokerages expect Prothena Corp (NASDAQ:PRTA) to announce earnings per share (EPS) of ($1.24) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prothena’s earnings, with estimates ranging from ($1.49) to ($0.83). Prothena reported earnings of ($0.99) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 25.3%. The business is expected to report its next earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Prothena will report full year earnings of ($5.35) per share for the current fiscal year, with EPS estimates ranging from ($6.51) to ($2.87). For the next financial year, analysts forecast that the firm will post earnings of ($4.10) per share, with EPS estimates ranging from ($5.84) to ($1.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Prothena.

How to Become a New Pot Stock Millionaire

Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $0.24. The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.27 million. Prothena had a negative net margin of 556.84% and a negative return on equity of 33.37%. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.41) earnings per share.

PRTA has been the subject of several recent research reports. Zacks Investment Research lowered shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $65.00 price target on shares of Prothena in a research report on Wednesday, December 20th. Oppenheimer set a $70.00 price target on shares of Prothena and gave the stock a “buy” rating in a research report on Thursday, February 15th. ValuEngine lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 7th. Finally, BidaskClub upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Friday, March 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $73.18.

Several institutional investors and hedge funds have recently bought and sold shares of the business. Delek Group Ltd. bought a new position in shares of Prothena in the fourth quarter worth approximately $1,123,000. Platinum Investment Management Ltd. boosted its position in shares of Prothena by 13.5% during the fourth quarter. Platinum Investment Management Ltd. now owns 70,400 shares of the biotechnology company’s stock worth $2,639,000 after acquiring an additional 8,400 shares during the last quarter. Millennium Management LLC bought a new position in shares of Prothena during the fourth quarter worth $338,000. HBK Investments L P bought a new position in shares of Prothena during the fourth quarter worth $213,000. Finally, Two Sigma Investments LP bought a new position in shares of Prothena during the fourth quarter worth $472,000.

NASDAQ PRTA traded up $0.28 during trading hours on Wednesday, hitting $38.25. 30,522 shares of the company’s stock traded hands, compared to its average volume of 540,256. The firm has a market capitalization of $1,464.29, a price-to-earnings ratio of -9.41 and a beta of 2.70. Prothena has a 52 week low of $27.19 and a 52 week high of $70.00.

ILLEGAL ACTIVITY WARNING: This piece was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://theolympiareport.com/2018/04/16/brokerages-expect-prothena-corp-prta-will-post-earnings-of-1-24-per-share.html.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.